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ABBREVIATIONS 
GABA: 7-aminobutyric acid; arKA: cr-ketogIutaric acid; SS: succinic 
semi a Idehyde; GAD: glutamic acid decarboxylase; GABA-T: 7-aminobutyric- 
a-ketogIutaric transaminase; SS-D: succinic semialdehyde dehydrogenase; 
Pa IP: pyridoxal phosphate; DPN: diphosphopyridine nucleotide; TPN: 
triphosphopyridine nucleotide; ADP: adenosine diphosphate; ATP: adenosi 
triphosphate; GDP: guanosine diphosphate; UDP: uridine diphosphate; 




Metabolism of Gamma-aminobutyric Acid in Brain 
The discovery of high concentrations of 7-aminobutyric acid in 
mammalian brain (1-4) focused interest on the possible functions of 
this amine in the central nervous system. Gamma-aminobutyric acid is 
formed in brain from glutamic acid through the action of a specific 
enzyme, glutamic acid decarboxylase (I, 3, 5), and is reversibly 
transami nated with or-ketog I utar i c acid, yielding glutamic acid and 
succinic semiaIdehyde, by means of another specific enzyme, 
7-aminobutyric-crketogIutaric transaminase (6, 7). Both of these 
enzymes are pyridoxal phosphate dependent, although the coenzyme is 
apparently more firmly bound to the apoenzyme in the transaminase than 
in the decarboxylase (8-10). Succinic semi aIdehyde, which is formed in 
the transamination reaction, is oxidized in brain to succinic acid 
(8, II), by a DPN dependent enzyme, succinic semialdehyde dehydrogenase 
(12, 13). 
Evidence for the participation of metabolites of C-14 labeled 
7-aminobutyric acid in the citric acid cycle has been obtained by 
several workers (II, 14, 15). The reactions catalyzed by the above 
mentioned enzymes provide an alternative pathway for 7-aminobutyric 
acid around succinyI-coenzyme A in the citric acid cycle, as shown in 
fig. I. The operation of this system has been demonstrated only in 
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pyruvic acid 
Fig. I. Metabolism of GABA in brain and its relationship to the citric 
acid cycle. Pathways shown are only those which have been definitely 
established. Note that for each mole of GABA metabolized to succinic 
acid, a mole of GA Is formed by transamination with crKA. GA Is then 
decarboxy Iated to GABA. 
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acid decarboxylase, 7-aminobutyric-a-ketogIu+aric transaminase, and 
succinic semialdehyde dehydrogenase (TPN dependent) have been found 
in microorganisms (16-21). Gamma-aminobutyric acid and glutamic acid 
decarboxylase have been isolated from a wide variety of plants (22, 23). 
Among the various tissues of higher animals, 7-aminobutyric acid and 
glutamic acid decarboxylase have been reported to occur naturally only 
in the central nervous system, and mainly in the gray matter. The 
decarboxylase, the transaminase, and the dehydrogenase are associated 
with the mitochondrial cell fractions. 
Function of Gamma-aminobutyric Acid 
Several theories have been advanced to explain the function of 
7-aminobutyric acid and the metabolic pathway in which it is involved. 
Evidence has been obtained that the amine may serve as a neurohumoraI 
inhibitory mediator, or that it may release such a substance (cf. ref. 
24). Gamma-aminobutyric acid perfusion slows and stops the crayfish 
heart, and opposes the action of acetylcholine in various invertebrate 
and vertebrate preparations (25-27). It inhibits the crayfish stretch 
receptor, and this characteristic is used in a biologic assay for the 
amino acid (28-30). It blocks excitatory synapes in the cat cerebraI 
cortex (31, 32), and depresses various excitatory electrical responses 
in the dog and rat cortices (33, 34), when applied locally to the 
exposed brain surfaces. Hydrazides, such as semicarbazide, inhibit 
the decarboxylase, decrease brain 7-aminobutyric acid, and produce 
convulsions when administered to mammals; convulsions are terminated 
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or prevented and EEG seizure patterns are diminished or obliterated 
by hydroxylamine, which increases brain 7-aminobutyric acid through 
inhibition of the transaminase (35-37). However, many data are 
reported, at least on a mammalian level, which make it difficult to 
ascribe any simple and direct neural impulse regulator function to 
this amino acid itself. No consistent correlation exists between 
7-aminobutyric acid concentrations in particular areas of the brain 
and seizure susceptibility of these areas (38). Hydroxy I amine fails 
to counteract thiosemicarbazide convulsions, yet it produces increased 
brain 7-aminobutyric acid levels (39). Central nervous system 
stimulation caused by various non-hydrazine agents, such as metrazole 
and strychnine, is not consistently accompanied by decreased 
7-aminobutyric acid concentration, nor is such stimulation necessarily 
counteracted by agents which raise its concentration (40). Topical 
application of 7-aminobutyric acid does not block spike potentials 
produced by strychnine or picrotoxin (41; cf. refs. 25, 140). 
A second line of evidence suggests that 7-aminobutyric acid 
functions as a precursor of several compounds and reactions which may 
play an important role in the nervous system (cf. ref. 42). Gamma- 
aminobutyryIcholine, which has characteristics of an inhibitory 
neurotransmitter and antagonizes many actions of acetylcholine, is 
probably formed from 7-aminobutyric acid in dog brain (43). Gamma- 
ami no-p-hydroxybutyric acid has been isolated as an oxidation product 
in guinea pig brain homogenate upon addition of ATP (44). This 
substance has an inhibitory action in the centra! nervous system 
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(27, 45, 46, 141), and blocks contractions of isolated mammalian 
intestine induced by acetylcholine (26). Its metabolism via oxidation 
and transamination has recently been investigated (47). Gamma-amino- 
(3-hydroxybutyry I-coenzyme A and 7-ami nobutyry I-coenzyme A have been 
reported to occur in brain extracts (48). An unidentified methylation 
product of 7-aminobutyric acid, formed in the presence of ATP, has a 
central nervous system excitatory action (45). The methyl ester of 
7-aminobutyric acid stimulates isolated mammalian intestine (49). 
Gamma-aminobutyryIlysine, 7-aminobutyrylarginine, and 7-aminobutyryI- 
histidine (homocarnosine) are formed in chicken muscle from the 
corresponding amino acids in the presence of ATP (50). The latter 
dipeptide has recently been isolated from steer brain (51). Gamma- 
guanidinobutyric acid, a substance with marked sedative effects (52), 
is synthesized from 7-aminobutyric acid and arginine in mammalian 
brain (53-55), and represents a potential mechanism for ammonia 
metabolism in the central nervous system (56, 57). Gamma-aminobutyric 
acid has been reported to react with inosine monophosphate to form 
adenylic acid in rat brain homogenate (58). Gamma-aminobutyric acid 
is formed from 7-butyrolactam (2-pyrroIidinone) in cat cerebra I 
cortex (59). The latter compound has anticonvulsant activity in 
mice (60). 
The importance of these various substances and reactions, and their 
relationship to the established 7-aminobutyric acid metabolic pathway 
shown in fig. I, is not understood. If 7-aminobutyric acid is a 
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exist in a combined form in brain. 
Several investigations suggest that 7-aminobutyric acid participates 
in an energy yielding metabolic pathway (fig. I). This pathway may 
regulate a part of the available energy in the central nervous system, 
and hence may control levels of functional neuronal activity. 
Malfunction in the nervous system might result from disturbances in 
the rates of turnover of substances in this pathway, even if the 
levels of 7-aminobutyric acid or a product were not significantly 
altered. Gamma-aminobutyric acid and succinic semialdehyde are reported 
to support respiration and oxidative phosphorylation in brain tissue 
preparations (II, 44, 61, 62) to an extent comparable to glutamic acid 
and glucose (63). Thus, all the 7-aminobutyric acid pathway metabolites 
apparently support oxidative metabolism. Both human (64) and animal 
(65) studies indicate that cerebral metabolic rate is reduced during 
pyridoxine deficient seizure activity, and emphasize the importance of 
pyridoxal phosphate in maintaining normal rates of oxygen consumption 
in brain (cf. ref. 66). The portion of a-ketogIutaric acid which is 
metabolized through the 7-aminobutyric acid alternative to succinic 
acid, rather than directly via succinyI-coenzyme A, has been determined 
by various investigators to be between 20 and 50 per cent (67-69). 
Presumably, the portion which passes via the 7-aminobutyric acid 
pathway, and the rate of metabolism through this system, are important 
for central nervous system energy and neuronal activity, but the factors 
which determine these quantities are incompletely known (68, 70, 71). 
It has been proposed that the 7-aminobutyric acid pathway may serve 
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a regulatory function for various brain biochemical reactions which 
are mediated through succinyI-coenzyme A by modifying the available 
concentration of the latter intermediate (72). The alternative 
7-aminobutyric acid pathway, which apparently does not produce 
succinyI-coenzyme A, may be a more economical one under some 
circumstances. This may spare succinyI-coenzyme A for use in other 
brain reactions. 
Much work is currently being done to elucidate the significance of 
7-aminobutyric acid and its metabolism. Several recent reviews and 
symposia discuss the biochemical and physiological investigations 
related to 7-aminobutyric acid (73-79, 139). 
Purpose of the Present Work 
The antibiotic cycloserine has been reported to inhibit various 
transaminases obtained from bacterial (80-82) and animal (83-86) 
sources. The greatest effects have been demonstrated with glutamic- 
pyruvic transaminase of rat brain (86), and with glutamic-oxaloacetic 
transaminase of human brain (83); inhibitions of 50# were obtained with 
-6 -5 
10 to 10 M cycloserine. A structural similarity between 
7-aminobutyric acid acid and cycloserine (see p. 37) suggested the 
possibility of a competitive antagonism between the two substances. 
In view of these considerations, investigations were carried out on 
the effects of cycloserine observed in vitro on 7-aminobutyric- 
crketogIutaric transaminase. 
It has been reported that !0~^ M D-cycloserine will produce up to 
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50# inhibition of glutamic acid decarboxylase obtained from E_. co I i , 
although the concentration must be increased to 10 M to obtain this 
degree of inhibition of the enzyme prepared from mouse brain (87). As 
has been indicated, some substances which inhibit the decarboxylase 
and lower brain 7-aminobutyric acid, including isonicotinic acid 
hydrazide (isoniazid) (88, 89), cause central nervous system excitation. 
Substances which counteract this excitatory effect inhibit the 
transaminase and raise brain 7-aminobutyric acid. Cycloserine exerts 
effects in the central nervous system, consisting of sedative and 
excitatory manifestations, observed clinically in man (90-92) and 
experimentally in animals (93-96). Hence, studies were conducted on 
the effects of cycloserine observed in vivo on 7-aminobutyric acid 
metabolism, as measured by changes in brain concentrations of the 




DL-cycloserine (aminoisoxazolidone) used in these experiments was 
kindly supplied by K. K. Chen of the Eli Lilly and Company, Indianapolis 
6, Indiana. Succinic semialdehyde ethyl ester was a gift of D. P. 
Wailach of the Upjohn Company, Kalamazoo, Michigan. This may also be 
obtained from Chemicals Procurement Company, 550 Fifth Avenue, New York 
36, New York. Ail other chemicals were supplied by commercial sources. 
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METHODS 
Preparation of Bacterial Enzyme 
Jakoby and Scott found high activities of 7-aminobutyric-a-ketogIutaric 
transaminase coupled with succinic semialdehyde dehydrogenase in a strain 
of Pseudomonas fluorescens, and used this system in an enzymatic assay 
of 7-aminobutyric acid (19, 20), by following the reduction of TPN 
spectrophotometricaIly (97). Wallach also isolated these enzymes from 
Escherichia coIi, strain ATCC-26, and utilized them for the same purpose 
(21). 
The E.. co I i organism was maintained on 10 ml slants of nutrient agar 
at 4°. Each month an innoculum from a slant was grown in nutrient broth 
at room temperature for 24 hours, and was then transferred to a fresh 
slant. 
For bacterial enzyme preparation, a 100 ml innoculum of cells grown 
in nutrient broth at room temperature was transferred into eight liters 
of the same medium. Air at 5 to 7 pounds pressure was bubbled through 
the medium for 24 hours. Several eight-1 iter cultures could be 
prepared at one time. 
The cells were harvested in the continuous flow apparatus of a 
Lourdes centrifuge. The yield was about 3 grams per liter. The cells 
were washed once in approximately 10 volumes of cold isotonic saline. 
They were then frozen, and could be kept for months at -20° without loss 
of enzyme activity. 
I 
To isolate bacterial enzyme, the cells were thawed and ground in 
twice their weight of cold alumina A-303. Alumina grinding gave better 
results than cracking the cells with glass beads, sonication, or 
protoplast formation with lysozyme and subsequent lysis in distilled 
water. Three volumes of 0.001 M magnesium acetate in 0.001 M Tris buffer, 
pH 7.2, were added in small aliquots during grinding, and the preparation 
was centrifuged for 10 minutes at about 5000 g to remove alumina and 
cellular debris. 0.25 volumes of 5# streptomycin were added slowly 
to the supernatant. The mixture was stirred for 30 minutes, and then 
centrifuged for 15 minutes at approximately 20,000 g to remove the 
precipitate of nucleic acid. An equal volume of 0.1 M potassium 
phosphate buffer, pH 7.4, containing 0.01# 2-mercaptoethanoI, was then 
added to the supernatant. The solution was brought to 55# saturation 
of ammonium sulfate by the slow addition of the solid compound, and the 
preparation was stirred for one hour. It was then centrifuged for 30 
minutes at 34,000 g. This fraction contains some of the desired enzymes, 
but the procedure removes alcohol dehydrogenase from the subsequent 
fraction. The latter enzyme might interfere slightly in the assay of 
brain 7-aminobutyric acid. 
Solid ammonium sulfate was slowly added to the supernatant to give 
a final saturation of 65#. The mixture was stirred for 30 minutes, 
and then centrifuged for 30 minutes at 34,000 g. The precipitate was 
dissolved in one volume of 0.I M potassium phosphate buffer, pH 7.4, 
containing 0.01# 2-mercaptoethanoI. This solution, the 55 to 65# ammonium 
sulfate fraction, contains the needed 7-aminobutyric-a-ketoglutaric 
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12 
transaminase and succinic semi aldehyde dehydrogenase. It was dialyzed 
against four liters of phosphate buffer for 24 hours, with one change 
of buffer. The dialyzed enzyme preparation was kept at -20°. A 
purification of the enzyme of about 80 fold is acheived by this method. 
All steps in both the bacterial and the brain enzyme extraction 
procedures were performed at approximately 4°. 
Preparation of Brain Enzyme 
Brain enzyme was prepared from acetone powders of whole brains 
of cats (FeIis domesticus) and rhesus monkeys (Macaca rhesus), as 
modified from the procedure of Baxter and Roberts for steer brain (10). 
Cats were sacrificed by intravenous injection of pentobarbital sodium; 
monkeys were given a blow on the head, the great vessels of the neck 
were severed, and the animals were exsanguinated. The brains were 
rapidly removed, and were either frozen and used within two days, or 
were blended immediately in 10 volumes of acetone at -20° in a glass 
cup of a Waring blendor. The preparation was filtered in a Buechner 
funnel under suction, and the resulting cake was twice blended in 5 
volumes of cold acetone and filtered. The powder was stored in a 
vacuum desiccator at 4° in the presence of silica gel and paraffin 
shavings. The crude brain preparation could be stored for several 
months in this state without loss of activity. 
To isolate brain enzyme, the powder was blended in 10 volumes of 
0.1 M Tris buffer, pH 8.2. The preparation was centrifuged at 34,000 g 
for 30 minutes. The supernatant was brought to 40$ saturation by the 
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13 
slow addition of solid ammonium sulfate, and the mixture was stirred 
for one hour. It was then centrifuged--first at 34,000 g for 30 
minutes in a Lourdes centrifuge, and then at 105,000 g for 30 minutes 
in a Spinco ultracentrifuge—and the precipitate was discarded. The 
supernatant was brought to 50$ saturation with ammonium sulfate, and 
was then centrifuged for 30 minutes at 34,000 g. The precipitate was 
dissolved in one volume of 0.1 M Tris, pH 8.2. The solution was 
dialyzed for 3 hours against 1000 ml of the Tris buffer with 6 changes 
of buffer, and was used on the same day. 
Brain enzyme was also prepared directly from fresh tissue. The 
brains were removed and blended immediately in 10 volumes of 0.1 M Tris, 
pH 8.2. The mixture was centrifuged for 30 minutes at 34,000 g, and 
ammonium sulfate fractionations were carried out in the same manner as 
were those of the acetone powder preparation. The bulk of the enzyme 
activity was contained in a 50 to 60$ fraction. Activity was lost with 
dialysis. No significant differences were observed in the kinetics and 
inhibition of the acetone powder and fresh preparations. 
A highly active TPN dependent isocitric dehydrogenase was present 
in the partially purified preparations from cat and monkey brain. 
Animal Procedures 
Experiments j_n vivo were conducted with adult male white rats 
(Spraque-Dawley strain) and 350 gram male and female guinea pigs (short- 
haired, mixed English type). These animals were given varying doses of 
cycloserine intraperitoneaI Iy. The brains were extracted with ethanol 
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for 7-aminobutyric acid analysis in a manner similar to that of Baxter 
and Roberts (35). Each animal was decapitated and the brain was quickly 
removed and weighed. The whole brain was homogenized in a glass 
homogenizer with Teflon pestle in 5 volumes of 70# ice cold ethanol. 
The homogen izer and pestle were rinsed in one volume of ethanol, and 
the rinsing were added to the homogenate. The homogenate was centrifuged 
at 5000 g for 15 minutes, and the supernatant was decanted. The 
precipitate was washed in 4 volumes of ethanol, and the washings were 
added to the supernatant. The extracts were then evaporated to dryness 
in a flash evaporator. One ml of distilled water was added to the 
dried extract for every gram of fresh weight of brain. The resuspended 
extract was then centrifuged at 105,000 g for 30 minutes in a Spinco 
u I tracentrifuge to remove lipoprotein. Aliquots of supernatant (0.05 
to 0.3 ml) were then assayed by the enzymatic method. 
Negligible losses of 7-aminobutyric acid are incurred during the 
procedure (98). Total brain 7-aminobutyric acid is determined, including 
both free and occluded forms, as described in the biologic assay using 
the crayfish stretch receptor (28-30). 
Preparation of Reagents 
AIpha-ketogIutaric acid was prepared in 0.1 M Tris, pH 8.5. This 
solution was made daily and kept cold to avoid slow degradation. 
Gamma-aminobutyric acid was dissolved in water, and could be stored 
indefinitely at refrigerator temperatures. Free succinic semialdehyde 
was prepared from the ethyl ester by hydrolysis in I M hydrochloric 
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acid in a boiling water bath for one hour. The solution was then 
cooled to 4°, buffered with potassium monohydrogen phosphate, and 
brought to pH 6.7 with sodium hydroxide (99, 6). The slightly acid 
solution was stable for several weeks at refrigerator temperatures. 
Cycloserine was prepared as a 0.01 M solution, and adjusted to pH 8.5 
with concentrated ammonium hydroxide. At this pH it can be stored at 4° 
without loss of activity for three to four days (100). However, it was 
prepared daily in order to avoid any possible effects of degradation 
products. 
Assay of Gamma-aminobutyric Acid 
The mixture added to a 3 ml Beckman cuvette for the determination 
of enzyme activity was as follows (21): 6 pmoles each of 7-aminobutyric 
acid and a-ketog I utar i c acid (or 6 pimoles of succinic semialdehyde); 
approximately 600 ixmoles of Tris buffer, pH 8.5; 5 ^moles of 
2-mercaptoethanoI; I mg of TPN or DPN; 0.1 ml of enzyme; water to a 
final volume of 3 ml. Appropriate changes in amounts of substrate and 
enzyme, and additions of cycloserine, were made when needed in the 
various kinetic and inhibition studies, in the preparation of standard 
curves for the assay of 7-aminobutyric acid, and in the assay of unknown 
samples. A new standard curve, a typical example of which is shown 
in fig. 2, was constructed whenever an assay was to be carried out, in 
order to compensate for slight changes in enzyme activity with 
different preparations and with freezing and thawing of the enzyme. 
Unknown samples contained 0.05 to 1.0 pimoles of 7-ami nobutyr ic acid. 
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Fig. 2. Standard curve for assay of GABA. 
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All reactions were carried out at room temperature. 
The production of glutamic acid was determined by unidimensionaI 
paper chromatography using N-butanoI-acetic acid-water (2:1:1) as 
solvent and ninhydrin as developer. Reaction mixtures were also assayed 
for the disappearance of orketogIutaric acid by the semicarbazide method 
of MacGee and Doudoroff (101). 
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RESULTS 
Properties of the Enzyme System Observed in vitro 
pH Range and Stability 
(a) Bacterial: The enzyme system prepared from E_. co I i was most 
stable in the pH range of 7.2 to 7.5. At slightly acid pH's it was 
rapidly inactivated. If the enzyme was not dialyzed it lost its 
activity in a few days. After dialysis, which removed excess ammonium 
sulfate and adjusted the pH to the optimum range, the enzyme system 
was stable at -20° for two to three months, providing excessive thawing 
and refreezing of the preparation was avoided. 
The bacterial enzyme system was most active in a reaction mixture 
at a pH of 8.2 to 8.5. 
(b) Brain: The enzyme system obtained from cat and monkey brain 
had an optimum pH range of 8.2 to 8.5 for both stability and activity. 
No significant differences were observed between the cat and the monkey 
preparations, nor between the acetone powder and the fresh preparations, 
in any of the studies. 
Succinic semialdehyde dehydrogenase was far more stable under the 
conditions of isolation employed than was 7-aminobutyric-a-ketogIutaric 
transaminase. The purified enzyme could be kept at -20 for at least two 
months without loss of the dehydrogenase activity, whereas it could not 
be frozen and had to be used on the day of preparation in order to 
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retain the transaminase activity. Perhaps the addition of small 
amounts of 7-aminobutyric acid during the purification procedure would 
increase the stability of the brain enzyme. 
Specificity 
(a) Bacterial: The enzyme system isolated from E. coIi did not 
reduce TPN in the presence of D-alanine, L-alanine, f3-alanine, or 
2,4-diaminobutyric acid. TPN was reduced about five times more rapidly 
than was DPN with either 7-aminobutyric acid and a-ketogIutaric acid, 
or with succinic semi a Idehyde, as substrates. 
(b) Brain: In contrast to the findings of Albers et. al. (12, 13), 
TPN was reduced by the enzyme prepared from cat and monkey brain with 
succinic semialdehyde as substrate; however, DPN was reduced twice as 
rapidly. With 7-aminobutyric acid and a-ketogIutaric acid as substrates, 
DPN was reduced about ten times as rapidly as TPN. These observations 
might be explained by the presence of small amounts of pyridine 
nucleotide transhydrogenase in the partially purified enzyme preparations 
(102, 103), along with traces of DPN in the commercial TPN used. 
Metal and Cofactor Requirements 
(a) Bacterial: No effect on the velocity of TPN reduction by the 
-3 +j 
bacterial enzyme system was observed with the addition of 10 M Mg 
or Mn++. Slight inhibition was seen in the presence of 10 J M Zn++. 
It was unnecessary to add pyridoxal phosphate for the transamination 
reaction to proceed. 
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(b) Brain: The addition of pyridoxal phosphate was not required 
with the crude brain enzyme, but added coenzyme increased the activity 
about twofold as the preparation was further purified. The optimum 
pyridoxal phosphate concentration was approximately 4 x I0~4 M (cf. 
ref. 10). The transamination reaction was inhibited slightly by excess 
pyridoxal phosphate. No effect was observed with the addition of ADP, 
GDP, or UDP and inorganic phosphate at concentrations of up to 3.3 x 10 ^ M. 
Inhibition by Cycloserine 
(a) Bacterial: Cycloserine inhibited 7-aminobutyric-a-ketogIutaric 
transaminase of co I i when the reaction was started by the addition 
of enzyme (table I, fig. 3). When cycloserine was allowed to remain in 
contact with the enzyme for 5 minutes in the absence of 7-aminobutyric 
acid, and the reaction was then started by the addition of the latter 
substrate, the inhibition was greatly enhanced (table I, fig. 3). The 
degree of inhibition was proportional to the length of time of incubation 
of enzyme and cycloserine prior to the addition of 7-aminobutyric acid 
at constant cycloserine concentration (table 2, fig. 4). When enzyme 
and cycloserine were incubated in the presence of 7-aminobutyric acid, 
and the reaction was then started after several minutes by the addition 
of a-ketogIutar i c acid, the inhibition was only slightly greater than 
that without prior incubation. More pronounced inhibition was 
observed with low concentrations of 7-aminobutyric acid (excess 
a-ketogIutaric acid) than with low concentrations of a-ketog I utar i c acid 
(excess 7-aminobutyric acid), as may be seen by comparing the slopes 
j. i ~i - , j .. 3 , .. : i ‘v. () 
, ' . .1- 0V/+ 
noi1 . \ i _ . 1 • ■ 
; . ( I 
. - ! I f "1V< ; 
.in. v "K... i 
; . i [ ' 'J 
I . ; i ■ i ’ ■ • i .. 
; . . i 
i ji ' . ( . i i i . r) 
.. . . i ... 
• I 
1 1 .) iV i 
. ' >'■- ! 
i i . i -.v ffi i 'T^SO ! 
1 . 1 , • i i 
! . >. 1 * 
. 1 1 1 . ..'in , 1 . 
... i . . : : i ■; i t. ., 
) ■ 1 t. i 1 . ' 1 
f ,. . . i '; i 
21 
Table I. DL-cycloserine Inhibition' of bacterial 7-aminobutyric- 
crketog I utar i c transaminase without incubation and with five minute 
incubation of enzyme and cycloserine in the absence of 7-aminobutyric 
acid. The reaction mixture contained 6 pmoles each of 7-ami nobutyr i c 
acid and cr-ketog I utar i c acid. 
Concentration 
of cycloserine 
Per cent inhibition 
with no incubation 
Per cent inhibition with 
five minute incubation 
I0"5 M 25$ 
I0~4 M 50$ 




I0~3 M 40$ > 95$ 
IC3 M 60$ 
*Per cent initial velocity with inhibitor present as compared to that 
with no inhibitor present, minus 100$. 
Table 2. Per cent inhibition of bacterial 7-ami nobutyr ic-cz-ketog I utar ic 
transaminase as a function of time of incubation of enzyme and cycloserine 
(6.5 x I0“4 M) in the absence of 7-aminobutyric acid. 
Time of incubation Per cent inhibition 
in minutes 
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Fig. 3. Cycloserine inhibition of bacterial y-aminobutyric-cr-ketog lutaric 
tramsaminase. The reaction mixture contained 6 ^moles each of GABA and 
OrKA. I: no cycloserine; II: 1.6xI0"3 M eye loserine, no incubation (A0% 
inhibition); III: I,6x10“^ M eyeloserlne, five minute Incubation of enzyme 
















Fig. 4. Per cent Inhibition as a function of time of incubation of bacterial 
enzyme and Inhibitor in the absence of GABA. The reaction mixture contained 
6 umoies each of GABA and cr-KA, with a cycloserine concentration of 6.5xl0“4 M. 
The relationship approximates the equation of a rectangular hyperbola. 
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with and without inhibitor in the Lineweaver-Burk plots. Thus, the 
presence of 7-aminobutyric acid, but not arketogIutaric acid, partially 
protects the enzyme from cycloserine inhibition. 
Enzyme concentrations were plotted against initial velocity of the 
reaction (Ackermann and Potter, 104), with 5 minute incubation of 
enzyme and cycloserine prior to starting the reaction by the addition 
of 7-aminobutyric acid. The intercepts of the slopes remained constant 
at the origin, but the slopes decreased with increasing concentrations 
of cycloserine (fig. 5). This demonstrated that the inhibition was 
apparently reversible under these conditions. 
A Lineweavei—Burk plot (105) revealed that the bacterial transaminase 
inhibition by cycloserine was competitive with respect to 7-aminobutyric 
acid (fig. 6). The MichaeIis-Menton constant (Km) for 7-aminobutyric 
acid (excess crketog I utar i c acid) and the inhibitor constant (Ki) were 
of nearly the same value (table 3). Hence, with competitive inhibition 
it was anticipated that approximately 50# inhibition would be produced 
with equal concentrations of 7-aminobutyric acid and cycloserine. It 
may be observed that this is so by reference to table I, in which it 
can be seen that a concentration of 2 x 10 ^ M cycloserine (6 p.moles) 
could be expected to produce an inhibition of about 50# in the presence 
of the same concentration of 7-aminobutyric acid. However, when 
excess 7-aminobutyric acid was added, the inhibition was not completely 
reversed. 
The measurements for the Lineweavei—Burk plot were obtained with 
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Fig. 5. Ackermann-Fitter graph, showing reversible inhibition of bacterial 
y-amlnobutyrIc-arketoglutarIc transaminase by cycloserine. Enzyme and 
Inhibitor were incubated in the absence of GABA for five minutes before the 
reaction was started. 6 ymoles each of GABA and orKA were present in the 
reaction mixture. I: no cycloserine; II: 3.3xl0”4 M cycloserine (502 
Inhibition); III: 6.5xI0“* M eye loser Ine (75# inhibition). 
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Fig. 6. Reciprocal of velocity of the reaction, catalyzed by bacterial enzyme, 
as a function of reciprocal of GABA concentration (I), and inhibition by 
cycloserine, 3.3x10 * H (II). Enzyme and cycloserine were not incubated before 
the reaction was Initiated. The inhibition Is competitive with respect to GABA. 
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Table 3. MlchaeI Is-Men+on constants (Km) and Inhibitor constants (Ki) 
for bacterial and brain transaminases, as obtained from Lineweavei— 
Burk plots (figs. 6, 7, 9, 10). Substrates were 7-aminobutyric acid 
(with 6 mmoles of a-ketogIutaric acid) or a-ketogIutaric acid (with 
6 nmoles of 7-ami nog Iutaric acid). Reactions were carried out at pH 
8.4 and TPN (bacterial enzyme) or DPN (brain enzyme) concentrations 
of 4 x I0-4 M. Cycloserine, 3.3 x I0“4 M, was not incubated with the 











a-KA 5.0 X I0~4 7.7 x I0~4 
Bra i n GABA 4.5 x I0~4 2.3 x I0"4 
transaminase 
crKA 6.7 x I0"4 2.7 x 
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and cycloserine were allowed to remain in contact for various intervals 
of time prior to the addition of 7-aminobutyric acid, the inhibition 
became mixed competitive and non-competitive, according to Lineweaver- 
Burk plots, and the calculated Ki values were somewhat smaller. Very 
little or no reversal of the inhibition was effected by the addition of 
excess 7-aminobutyric acid (12 mmoles) under these conditions. 
Cycloserine inhibition was non-competitive with respect to 
a-ketoglutaric acid when the reaction was started by the addition of 
enzyme (fig. 7, table 3). When enzyme and cycloserine were incubated 
for several minutes prior to the initiation of the reaction by the 
addition of 7-aminobutyric acid, the inhibition was of a much greater 
degree, as in the previous experiments, but remained non-competitive 
with respect to crketogIutaric acid, according to Lineweaver-Burk plots. 
The inhibition produced by cycloserine was not reversed by the 
addition of pyridoxal phosphate, glutathione, or cysteine at 
—3 —3 ++ 11 -f-f. 
concentrations of 5 x 10 M, nor by 10 M Mg , Mn'*' , or Zn 
Cycloserine at concentrations of I0~4 to 10 M had no effect on the 
bacterial succinic semi aldehyde dehydrogenase, as shown by the absence 
of inhibition when succinic semialdehyde was the substrate. The 
presence of hydroxylamine, an acid hydrolysis product of cycloserine 
(106, 107), and a potent inhibitor of 7-aminobutyric-a-ketogIutaric 
transaminase (35-37), was not revealed by the acetic anhydride- 
ferric chloride test (108), even when cycloserine had been stored at 
o 
4 for two months. DL-serine, the other acid hydrolysis product (106, 
107), produced no inhibitory effect on either the transaminase or the 
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Fig. 7. Same as figure 6, but with reciprocals of cr-KA concentrations on the 
abscissa. J: no cycloserine; II: 3.3xI0”4 M eye loser Ine. The inhibition is 




dehydrogenase at concentrations of 10 M. 
(b) Brain: Cycloserine inhibited 7-aminobutyric-crketogIutaric 
transaminase of cat and monkey brain to a greater extent than the 
bacterial preparation when the reaction was started by the addition 
-4 
of enzyme. The inhibition was 50# at 6.5 x 10 M and 90# at 
1.6 x I0'J M cycloserine concentrations (cf. table I). Incubation 
of enzyme and cycloserine prior to the addition of 7-aminobutyric acid 
produced increased inhibition, although not to as marked a degree as with 
the E_. coI i enzyme. Equimolar amounts of cycloserine and pyridoxal 
phosphate were premixed and allowed to remain in contact for various 
intervals of time before being added to the reaction mixture. This 
procedure resulted in slightly increased inhibition. Inhibition was 
increased to a similar slight extent when cycloserine and pyridoxal 
phosphate, plus enzyme and 7-aminobutyric acid, were premixed, and 
then the reaction was started after several minutes by the addition of 
DPN and crketogIutaric acid. Isoniazid, which inhibits some pyridoxal 
phosphate dependent enzymes (109-112), had no effect on the reaction 
at concentrations of 10 J M. 
Cycloserine inhibition of the brain transaminase was of the 
reversible type, under the conditions recorded in fig. 8, as shown by 
an Ackermann-Potter plot (104). The inhibition was mixed competitive 
and non-competitive with respect to 7-aminobutyric acid, whether or not 
enzyme and cycloserine were allowed to remain in contact prior to the 
addition of the amino acid (fig. 9). Cycloserine inhibition was non¬ 
competitive with respect to crketogIutaric acid (fig. 10). The Km 
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Fig. 8. Ackermann-Potter graph, showing reversible inhibition of brain 
y-amlnobutyrlc-orketog lutarIc transaminase by cycios®rin«. Five minute incubation 
of enzyme and cyclos®rln® in th® absence of GABA was carried out before the 
reaction was Initiated. 6 pinoles each of GABA and cr-KA were present in the 
reaction mixture. I: no cycloserine; II: 3.3xI0-4 M eye loser Ine (60# inhibition); 





















Fig. 9. LIneweaver-Burk plot with brain enzyme, using GABA as the independent 
variable. I: no cycloserine; II: 3.3x10"*^ M cycloserine. The inhibition is 






















Fig* 10* Same as figure 9, but with oc-KA as the independent variable. I: no 
cycloserine; II: 3.3x10*“^ H cycloserine. The inhibition is non-competitive. 
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and Ki values for each of these reactants is shown in table 3. 
The inhibition produced by cycloserine could not be reversed by 
-2 
excess pyridoxal phosphate. Cycloserine at 10 M concentration had 
no effect on the brain succinic semialdehyde dehydrogenase. 
Cycloserine inhibition of both the bacterial and the brain 
transaminases was enhanced with greater enzyme purification, and 
diminished with greater age of the preparations (cf. ref. 86). This 
may be due to non-specific binding of cycloserine by sites other than 
those of the active enzyme, or to inactivation of the drug by the 
crude or aged preparations. 
The enzyme kinetics and inhibition studies on both the bacterial and 
the brain preparations are thought to be relevant to the transaminase, 
even though the rates were actually measured by the dehydrogenase 
reaction, because (a) the dehydrogenase is not rate limiting since it 
has a very small Km (13, 72), and (b) cycloserine has no inhibitory 
effect on the dehydrogenase. However, it is possible that some 
differences would appear if the rate of the transaminase reaction were 
determined directly. 
Cycloserine Effects Observed in vivo 
Cycloserine injected intraperitoneaIly in rats and guinea pigs 
resulted in an increase in brain 7-aminobutyric acid concentration 
which was proportional to dosage (table 4). This occurred whether the 
drug was given in a single dose or over a period of several days. 
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Table 4. The effect of cycloserine observed in vivo on brain 
7-aminobutyric acid concentrations in the rat and the guinea pig. 
Animal No. of animals Dose of cycloserine Interval oefore GABA in brain 
per group (mg/lOOgm body wt.) sacrifice (jj.mo les/gm) 
Rat 2 saline 3 hr., 2 da. 2.5 
1 80 3 hr. 2.8 
2 600* 2 da. 7.3 
Guinea pig 2 saline 3 hr., 7 da. 1 .3 
1 300 3 hr. 1.5 
1 450 3 hr. 1 .8 
1 700 3 hr. 2.4 
1 I000+ 7 da. 3.4 
* 
Tota 1 amount per lOOgm body weight given in 125 mg doses four times a day. 
+Tota1 amount per lOOgm body weight given in 250 mg doses twice a day. 
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concentrations and more marked toxic side effects. This is probably 
attributable to a larger total amount of drug given, and to the effect 
of more sustained blood levels. 
Physical manifestations seen following cycloserine administration 
were similar in both species. Animals appeared moderately lethargic 
and sedated, but exhibited generalized twitchings at variable intervals. 
There was an accentuated startle response. All animals performed 
peculiar, rapid face-washing movements. With prolonged administration, 
there was hyperventilation, decreased tone, ataxia, and more 
pronounced twitchings (cf. refs. 93, 94). None of these effects was 
observed in the saline injected controls. 
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DISCUSSION 
Studies in vitro 
Structural similarities of cycloserine and 7-aminobutyric acid 
suggest a basis for the competitive inhibition of the transaminase 
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The inhibition depended on the length of time of incubation of 
cycloserine and enzyme prior to the addition of 7-aminobutyric acid, 
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mixture. Also, the inhibition was not completely reversed with 
excess 7-aminobutyric acid, even when the reaction was started by 
the addition of enzyme. These findings indicate that competitive 
inhibition with respect to 7-aminobutyric acid does not completely 
explain the interaction of cycloserine and 7-aminobutyric-crketogIutaric 
transaminase, and suggest that a second type of inhibition is occurring. 
Pyridoxa! phosphate and cycloserine are reported to form a Schiff 
base in vitro (82). It has been demonstrated that non-enzymatic 
indole formation from tryptophan, in the presence of pyridoxaI, is 
-3 -2 
inhibited by high concentrations of cycloserine (10 to 10 M) 
(113, 80), and that cycloserine inhibition of tryptophanase, a 
pyridoxaI phosphate dependent enzyme, varies with the length of time 
of incubation of the drug and the coenzyme prior to the initiation 
of the reaction (82, 113). Several investigators have shown that 
other pyridoxaI phosphate dependent enzymes are inhibited by high 
concentrations of cycloserine, and have suggested that the inhibition 
is due to Schiff base formation between the antibiotic and pyridoxaI 
phosphate (114, 80). It is unlikely that this is an important 
mechanism in the inhibition of 7-aminobutyric-a-ketog Iutaric 
transaminase, since premixing of cycloserine and pyridoxal phosphate 
gave only slightly increased inhibition of the brain transaminase 
(cf. refs. I 15-117). 
It has also been suggested that Schiff base formation may play a 
significant role in cycloserine inhibition of pyridoxal phosphate 
dependent enzymes through a stabilization by the apoenzyme of the 
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I • J 
1 n ; i ■; ! J 
I - ( 
. ; I . i . . . ) 
I 
39 
otherwise readily dissociable Schiff complex (118^ 119). In the 
present study, however, the inhibition was again only slightly 
increased when all components except a-ketogIutaric acid were mixed 
and allowed to remain in contact for several minutes, and then the 
reaction was begun by the addition of the latter substrate. Hence, 
Schiff base formation between cycloserine and coenzyme is apparently 
not promoted by the presence of the apoenzyme. Moreover, potent 
carbonyl reagents which might be expected to form Schiff bases, such as 
isoniazid and semicarbazid, do not inhibit the transaminase (10)*. 
The addition of pyridoxal phosphate partially reactivates 
hydroxylamine inhibited brain /-aminobutyric-a-ketogIutaric transaminase, 
in which apoenzyme and coenzyme are loosely associated, but has no 
effect on the inhibited £. coIi transaminase, in which apoenzyme and 
coenzyme are tightly bound (120). This suggests that hydroxylamine is 
reacting with the coenzyme. But in the present study, added pyridoxal 
phosphate did not reactivate either the brain or the bacterial 
transaminase after cycloserine inhibition. Also, incubation of enzyme 
and cycloserine prior to the addition of /-aminobutyric acid produced a 
greater increase in inhibition, as compared to that with no incubation, 
in the bacterial than in the brain transaminase, whereas the reverse 
* Isoniazid at concentrations of lO--1 M was found to have no effect on 
glutamic-oxaloacetic transaminase from human brain, whereas I0~^ M 
D-cycloserine produced 50% inhibition of this enzyme (83). In another 
study, significant inhibition of glutamic-oxaloacetic transaminase from 
pig heart by carbonyl reagents, including isoniazid, was achieved only 
at high concentrations of inhibitor (I0~2 M) (110). 
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would be expected if the drug were exerting a primary effect on the 
coenzyme. 
It has been proposed that the effect of high concentrations of 
cycloserine on transaminases may be due to a resemblance between the 
carbonyl group of the antibiotic and the aldehyde group of pyridoxa! 
phosphate (83, 86). In this respect it should again be noted that in 
the present study the effect of the inhibitor was not reversed by 
excess coenzyme. Administration of vitamin Bg, reduces but does not 
eliminate cycloserine toxicity clinically, and animal experiments have 
not shown that the antibiotic produces or enhances vitamin depletion 
(91). However, cycloserine, at least in high concentrations, inhibits 
glutamic acid decarboxylase and many transaminases (80-86), all of 
which are pyridoxal phosphate dependent, and it is probable that this 
agent may exert some effect on pyridoxal phosphate in these enzymes. 
Cycloserine is known to chelate several divalent metals, most 
strongly copper and zinc (121). It has been shown that the drug 
inhibits non-enzymatic indole formation from tryptophan, with copper 
rather than pyridoxal as cofactor (82). Cycloserine inhibits the 
copper containing enzyme ascorbic acid oxidase (82), although there 
is some question as to whether copper activates or inhibits this enzyme 
(122, 123). Of several dehydrogenases examined in tubercle bacilli, 
cycloserine inhibited only malic dehydrogenase (124). It has been 
reported that this enzyme contains copper and zinc in mammalian 
preparations (125). Various catalases prepared from both bacterial 
and mammalian sources are inhibited by cycloserine (124, 126, 127). 
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These enzymes are said to contain or be activated by copper (128, 129). 
No evidence was obtained in the present study, however, that the drug 
acts by chelating copper or some other divalent metal necessary for the 
activation of 7-aminobutyric-a-ketogIutaric transaminase (cf. ref. 130) 
This could be investigated further by studying the effect of chelating 
agents, such as ethyIenediaminetetraacetic acid, on a more purified 
preparation of the enzyme. 
The fact that the degree of inhibition progressively increased and 
eventually became complete after 30 minutes of incubation of enzyme 
and cycloserine in the absence of 7-aminobutyric acid (table 2, fig. 4) 
suggests that a slow, perhaps irreversible inhibition was occurring. 
The flattening out of curve II, fig. 3, is indicative of this slow, 
progressive inhibition, which is also manifested when the reaction is 
begun by the addition of enzyme, for as the reaction proceeds and 
7-aminobutyric acid is transaminated, it is no longer available to 
protect the enzyme. The longer this reaction continues the less 
reversibiIity can be achieved by the addition of excess 7-aminobutyric 
acid. The inhibition of the enzyme when incubated with cycloserine 
for several minutes was not reversed by the addition of substrate, 
coenzyme, or any of various possible cofactors or activators. 
This apparent irreversibiIity, however, is not consistent with 
the Ackermann-Potter plots (figs. 5 and 8), which indicate that the 
inhibition is reversible. Incubation of enzyme and cycloserine for 10 
minutes prior to the addition of 7-aminobutyric acid produced slopes 
which were less steep than those of figs. 5 and 8, but which similarly 
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passed through the origin. It is possible, however, if incubation were 
carried out for a longer time than this before the addition of 
7-aminobutyric acid, that an Ackermann-Potter plot would show some 
titration of enzyme with inhibitor in an irreversible complex. However, 
it is equally possible that other methods, such as extensive dialysis 
or dilution (131, 132), would bring about at least a partial reversal 
of the cycloserine inhibited enzyme. 
It is concluded (a) that cycloserine is competitive with respect 
to 7-aminobutyric acid, non-competitive with respect to a-ketogIutaric 
acid, and produces a rapid, reversible inhibition, and (b) that 
cycloserine may react with the apoenzyme, the active center of which 
is protected by 7-aminobutyric acid, in a slowly progressive inhibition, 
which is not readily reversible (cf. refs. I 10, 133-135). The lack of 
complete reversibiIity of the competitive aspect of inhibition is 
undoubtedly due to this slow, second type of inhibition. The chemical 
nature of this latter inhibition is unknown, although it may be due to 
strong hydrogen bonding or to chelation with a metal group, or possibly 
to the formation of a covalent bond, in a truly irreversible inhibition. 
In view of the demonstrated complex nature of the interaction of 
cycloserine and 7-aminobutyric-a-ketogIutaric transaminase, it is 
thought that a more detailed study of the inhibition can profitably be 
undertaken only with a more highly purified enzyme preparation. 
Studies in vivo 
The finding that cycloserine increased brain 7-aminobutyric acid 
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concentrations in the rat and guinea pig is evidence that in vivo the 
drug inhibited the transaminase to a greater extent than the decarboxylase. 
This is consistent with the effects observed with the purified enzyme 
preparations in vitro (87). Cycloserine is an agent which both raises 
brain 7-aminobutyric acid and produces central nervous system excitation, 
comparable to the combined effects of hydroxylamine and thiosemicarbazide. 
This constitutes further evidence that a simple increase in 
7-aminobutyric acid does not protect against heightened central nervous 
system activity, although it does not rule out the possibility that 
seizures may be related to a lowered rate of 7-aminobutyric acid 
turnover (136). 
With the present state of investigation it is not possible to 
advance a unified theory for the role of the 7-aminobutyric acid pathway. 
Studies on the properties of succinic semialdehyde and its associated 
dehydrogenase, both of which are important participants in this pathway, 
have only recently been initiated (12, 13, 137). Further elucidation 
of the significance of the 7-aminobutyric acid system may be anticipated 
with greater knowledge of the properties of the enzymes involved and 
of their intraceI IuIar localization, and with correlation of these 
studies with membrane potentials and electrical events measured 
intraceI IuIarIy (138). The use of other substances with an inhibitory 
effect on the 7-aminobutyric acid system could provide valuable information. 
One such compound might be the new anti-neoplastic agent, hadacidin (142), 
which is structurally similar to cycloserine and 7-aminobutyric acid. 
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SUMMARY 
Experimental evidence relating to the function of 7-aminobutyric 
acid and its metabolism have indicated: (I) that 7-aminobutyric acid 
may serve as a neurohumoral inhibitory mediator, (2) that it may be a 
precursor for various other physiologically and biochemically active 
substances, and (3) that the rate of its metabolism may be important 
for central nervous system activity, possibly by regulating available 
energy. 
The fact that several transaminases have been shown to be strongly 
inhibited by cycloserine, and the structural similarities between the 
antibiotic and 7-aminobutyric acid, led to the present study in vitro 
on the interaction of 7-aminobutyric-a-ketogIutaric transaminase and 
cycloserine. The reported inhibition of glutamic acid decarboxylase 
by the drug, and its known central nervous system toxicity, were 
preliminary to a study of the in vivo effects of cycloserine on brain 
7-aminobutyric acid concentrations. 
A method was developed, as modified from Wallach, for the extraction 
of 7-aminobutyric-a-ketogIutaric transaminase and succinic semi aldehyde 
dehydrogenase from E. coIi, and this enzyme system was used in an assay 
of 7-aminobutyric acid. 
The transaminase, as prepared from E, coI 1 and from cat and monkey 
brain, was inhibited by cycloserine. The initial inhibition was 
reversible, competitive with respect to 7-aminobutyric acid, and 
non-competitive with respect to a-ketogIutaric acid. The degree of 
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inhibition depended on the length of time of incubation of cycloserine 
and enzyme prior to the addition of 7-aminobutyric acid. The subsequent 
addition of the latter substance did not reverse the inhibition of the 
enzyme when so incubated, although it did partially protect the enzyme 
from the inhibition if present initially. Hence, two types of inhibition 
were thought to occur: one was rapid and reversible; the other was 
slow, progressive, and not readily reversible. 
It was believed that cycloserine may have been interacting with 
the apoenzyme rather than with the coenzyme in the inhibition 
mechanism. 
Cycloserine raised brain 7-aminobutyric acid concentrations when 
injected intraperitonea1ly in rats and guinea pigs. This was 
attributed to an inhibition of the transaminase in vivo. At the same 
time the drug produced central nervous system excitatory effects. 
This was further evidence in disagreement with the theory that 
7-aminobutyric acid acts as an inhibitor of excitatory impulses. 
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